Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 3, 2014, Pages 328-337

  Siebeneicher, S ^a   Reuter, S ^b   Krause, M ^a   Wangorsch, A ^a   Maxeiner, J ^b   Wolfheimer, S ^a   Schulke S ^a   Naito, S ^c   Heinz, A ^b   Taube, C ^d   Vieths, S ^a   Scheurer, S ^a   Toda, M ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adjuvant; birch pollen allergy; epicutaneous immunization; R848; TLR7 agonist

Indexed keywords

ADJUVANT; BIRCH POLLEN ALLERGY; EPICUTANEOUS IMMUNIZATION; R848; TLR7 AGONIST;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS, PLANT; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MICE; PREMEDICATION; RECOMBINANT PROTEINS; TH1 CELLS;

EID: 84894280387     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12326     Document Type: Article

References (43)

1. Frew AJ,. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125: S306-S313.
2. Calderõn MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P,. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67: 302-311.
3. Senti G, von Moos S, Kündig TM,. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011; 66: 798-809.
4. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH,. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010; 40: 659-667.
5. Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011; 186: 5629-5637.
6. Mondoulet L, Dioszeghy V, Larcher T, Ligouis M, Dhelft V, Puteaux E, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro- enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS ONE 2012; 7: e31967.
7. von Moos S, Johansen P, Waeckerle-Men Y, Mohanan D, Senti G, Häffner A, et al. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy 2012; 67: 638-646.
8. Senti G, Graf N, Haug S, Rüedi N, von Moos S, Sonderegger T, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124: 997-1002.
9. Dupont C, Kalach N, Soulaines P, Legoué-Morillon S, Piloquet H, Benhamou PH,. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010; 125: 1165-1167.
10. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129: 128-135.
11. Jutel M, Akdis CA,. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011; 66: 725-732.
12. Nguyen TH, Casale TB,. Immune modulation for treatment of allergic disease. Immunol Rev 2011; 242: 258-271.
13. Schülke S, Burggraf M, Waibler Z, Wangorsch A, Wolfheimer S, Kalinke U, et al. A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy. J Allergy Clin Immunol 2011; 128: 1340-1348.
14. Kumagai Y, Akira S,. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol 2010; 125: 985-992.
15. Lacour F,. Polyadenylic-polyuridylic acid: biological response-modifying activities in mice. In vivo organ distribution and pharmacokinetics in rabbits. J Biol Response Mod 1985; 4: 490-494.
16. Wang L, Smith D, Bot S, Dellamary L, Bloom A, Bot A,. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 2002; 110: 1175-1184.
17. Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 2008; 19: 520-526.
18. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP,. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 2007; 6: 835-847.
19. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF,. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13: 859-875.
20. Quarcoo D, Weixler S, Joachim RA, Stock P, Kallinich T, Ahrens B, et al. Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin Exp Allergy 2004; 34: 1314-1320.
21. Sel S, Wegmann M, Sel S, Bauer S, Garn H, Alber G, et al. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol 2007; 178: 7805-7813.
22. Xirakia C, Koltsida O, Stavropoulos A, Thanassopoulou A, Aidinis V, Sideras P, et al. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010; 181: 1207-1216.
23. Grela F, Aumeunier A, Bardel E, Van LP, Bourgeois E, Vanoirbeek J, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J Immunol 2011; 186: 284-290.
24. Van LP, Bardel E, Gregoire S, Vanoirbeek J, Schneider E, Dy M, et al. Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms. Eur J Immunol 2011; 41: 1992-1999.
25. Kaul S, Lüttkopf D, Kastner B, Vogel L, Höltz G, Vieths S, et al. Mediator release assays based on human or murine immunoglobulin E in allergen standardization. Clin Exp Allergy 2007; 37: 141-150.
26. Reuter S, Dehzad N, Martin H, Böhm L, Becker M, Buhl R, et al. TLR3 but not TLR7/8 ligand induces allergic sensitization to inhaled allergen. J Immunol 2012; 188: 5123-5131.
27. Qaseem AS, Sonar S, Mahajan L, Madan T, Sorensen GL, Shamji MH, et al. Linking surfactant protein SP-D and IL-13: implications in asthma and allergy. Mol Immunol 2012; 54: 98-107.
28. Takatsu K, Kouro T, Nagai Y,. Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol 2009; 101: 191-236.
29. Nakagome K, Okunishi K, Imamura M, Harada H, Matsumoto T, Tanaka R, et al. IFN-gamma attenuates antigen-induced overall immune response in the airway as a Th1-type immune regulatory cytokine. J Immunol 2009; 183: 209-220.
30. Fernandez-Botran R, Sanders VM, Mosmann TR, Vitetta ES,. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med 1988; 168: 543-548.
31. Xu L, Rothman P,. IFN-gamma represses epsilon germline transcription and subsequently down-regulates switch recombination to epsilon. Int Immunol 1994; 6: 515-521.
32. Tang Y, Guan SP, Chua BY, Zhou Q, Ho AW, Wong KH, et al. Antigen-specific effector CD8 T cells regulate allergic responses via IFN-γ and dendritic cell function. J Allergy Clin Immunol 2012; 129: 1611-1620.
33. + T cells. J Exp Med 1993; 177: 573-576.
34. Zindler E, Gehrke N, Luft C, Reuter S, Taube C, Finotto S, et al. Divergent effects of biolistic gene transfer in a mouse model of allergic airway inflammation. Am J Respir Cell Mol Biol 2008; 38: 38-46.
35. + Th1 responses. PLoS ONE 2011; 6: e29412.
36. Haapakoski R, Karisola P, Fyhrquist N, Savinko T, Lehtimäki S, Wolff H, et al. Toll-like receptor activation during cutaneous allergen sensitization blocks development of asthma through IFN-gamma-dependent mechanisms. J Invest Dermatol 2013; 133: 964-972.
37. Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS ONE 2012; 7: e41501.
38. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL, et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 2009; 15: 1377-1382.
39. Hasan M, Ruksznis C, Wang Y, Leifer CA,. Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses. J Immunol 2011; 187: 5653-5659.
40. Fujita H, Asahina A, Mitsui H, Tamaki K,. Langerhans cells exhibit low responsiveness to double-stranded RNA. Biochem Biophys Res Commun 2004; 319: 832-839.
41. Scheiblhofer S, Thalhamer J, Weiss R,. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Expert Opin Drug Deliv 2013; 10: 761-773.
42. Kim YC, Park JH, Prausnitz MR,. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64: 1547-1568.
43. Beck LA, Leung DY,. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000; 106 (Suppl 5): S258-S263.